AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

bioAffinity Technologies, Inc. Director's Dealing 2024

Jul 3, 2024

35439_dirs_2024-07-02_cfaa85e6-f3dd-476d-af1b-8e72ef3979cb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2024-07-01

Reporting Person: DIAMOND STUART (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-07-01	Common Stock	A	33784	—	Acquired	99088	Direct

Footnotes

F1: Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024.